{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:49:38Z","timestamp":1761821378762},"publisher-location":"Cham","reference-count":236,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783319538884"},{"type":"electronic","value":"9783319538891"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-319-53889-1_23","type":"book-chapter","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T07:13:29Z","timestamp":1495091609000},"page":"443-475","source":"Crossref","is-referenced-by-count":4,"title":["Stem Cell Technology for (Epi)genetic Brain Disorders"],"prefix":"10.1007","author":[{"given":"Renzo J. M.","family":"Riemens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edilene S.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Esteller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"Delgado-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,19]]},"reference":[{"key":"23_CR1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd.2016.175","volume":"15","author":"P Horvath","year":"2016","unstructured":"Horvath P, Aulner N, Bickle M, Davies AM, Del Nery E, Ebner D, et al. Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov. 2016;15:751\u201369.","journal-title":"Nat Rev Drug Discov"},{"key":"23_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/9464591","volume":"2016","author":"R Fern\u00e1ndez-Santiago","year":"2016","unstructured":"Fern\u00e1ndez-Santiago R, Ezquerra M. Epigenetic research of neurodegenerative disorders using patient iPSC-based models. Stem Cells Int. 2016;2016:1\u201316.","journal-title":"Stem Cells Int"},{"key":"23_CR3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrm.2016.8","volume":"17","author":"K Takahashi","year":"2016","unstructured":"Takahashi K, Yamanaka S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol. 2016;17:183\u201393.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"23_CR4","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663\u201376.","journal-title":"Cell"},{"key":"23_CR5","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cell.2008.02.010","volume":"132","author":"LL Rubin","year":"2008","unstructured":"Rubin LL. Stem cells and drug discovery: the beginning of a new era? Cell. 2008;132:549\u201352.","journal-title":"Cell"},{"key":"23_CR6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40035-015-0039-8","volume":"4","author":"F Han","year":"2015","unstructured":"Han F, Baremberg D, Gao J, Duan J, Lu X, Zhang N, et al. Development of stem cell-based therapy for Parkinson\u2019s disease. Transl Neurodegener. 2015;4:16.","journal-title":"Transl Neurodegener"},{"key":"23_CR7","first-page":"105172","volume":"2015","author":"MS Yap","year":"2015","unstructured":"Yap MS, Nathan KR, Yeo Y, Lim LW, Poh CL, Richards M, et al. Neural differentiation of human pluripotent stem cells for nontherapeutic applications: toxicology, pharmacology, and in vitro disease modeling. Stem Cells Int. 2015;2015:105172.","journal-title":"Stem Cells Int"},{"key":"23_CR8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/978-1-61779-201-4_30","volume":"767","author":"L Ma","year":"2011","unstructured":"Ma L, Liu Y, Zhang SC. Directed differentiation of dopamine neurons from human pluripotent stem cells. Methods Mol Biol. 2011;767:411\u20138.","journal-title":"Methods Mol Biol"},{"doi-asserted-by":"crossref","unstructured":"Santos DP, Kiskinis E. Generation of spinal motor neurons from human pluripotent stem cells. Synap Dev Methods Protoc. 2017;53\u201366","key":"23_CR9","DOI":"10.1007\/978-1-4939-6688-2_5"},{"key":"23_CR10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.nbt.2014.05.001","volume":"32","author":"NL Payne","year":"2015","unstructured":"Payne NL, Sylvain A, O\u2019Brien C, Herszfeld D, Sun G, Bernard CCA. Application of human induced pluripotent stem cells for modeling and treating neurodegenerative diseases. New Biotechnol. 2015;32:212\u201328.","journal-title":"New Biotechnol"},{"key":"23_CR11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.conb.2015.11.003","volume":"36","author":"Z Wen","year":"2016","unstructured":"Wen Z, Christian KM, Song H, Ming G. Modeling psychiatric disorders with patient-derived iPSCs. Curr Opin Neurobiol. 2016;36:118\u201327.","journal-title":"Curr Opin Neurobiol"},{"key":"23_CR12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/nbt.1685","volume":"28","author":"A Portela","year":"2010","unstructured":"Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057\u201368.","journal-title":"Nat Biotechnol"},{"issue":"Pt A","key":"23_CR13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuropharm.2013.08.035","volume":"76","author":"JL Badger","year":"2014","unstructured":"Badger JL, Cordero-Llana O, Hartfield EM, Wade-Martins R. Parkinson\u2019s disease in a dish - Using stem cells as a molecular tool. Neuropharmacology. 2014;76(Pt A):88\u201396.","journal-title":"Neuropharmacology"},{"key":"23_CR14","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s11910-012-0288-1","volume":"12","author":"J Pu","year":"2012","unstructured":"Pu J, Jiang H, Zhang B, Feng J. Redefining Parkinson\u2019s disease research using induced pluripotent stem cells. Curr Neurol Neurosci Rep. 2012;12:392\u20138.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"23_CR15","volume":"6","author":"JV Sanchez-Mut","year":"2016","unstructured":"Sanchez-Mut JV, Heyn H, Vidal E, Moran S, Sayols S, Delgado-Morales R, et al. Human DNA methylomes of neurodegenerative diseases show common epigenomic patterns. Transl Psychiatry. 2016;6:e718.","journal-title":"Transl Psychiatry"},{"key":"23_CR16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pneurobio.2015.05.002","volume":"131","author":"R Lardenoije","year":"2015","unstructured":"Lardenoije R, Iatrou A, Kenis G, Kompotis K, Steinbusch HW, Mastroeni D, et al. The epigenetics of aging and neurodegeneration. Prog Neurobiol. 2015;131:21\u201364.","journal-title":"Prog Neurobiol"},{"key":"23_CR17","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","volume":"8","author":"P Damier","year":"1999","unstructured":"Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson\u2019s disease. Brain. 1999;8:1437\u201348.","journal-title":"Brain"},{"key":"23_CR18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2741\/S415","volume":"6","author":"JM Beitz","year":"2014","unstructured":"Beitz JM. Parkinson\u2019s disease: a review. Front Biosci (Schol Ed). 2014;6:65\u201374.","journal-title":"Front Biosci (Schol Ed)"},{"key":"23_CR19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11910-012-0270-y","volume":"12","author":"B Byers","year":"2012","unstructured":"Byers B, Lee HL, Reijo PR. Modeling Parkinson\u2019s disease using induced pluripotent stem cells. Curr Neurol Neurosci Rep. 2012;12:237\u201342.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"23_CR20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1248\/bpb.b12-00929","volume":"36","author":"K Nishimura","year":"2013","unstructured":"Nishimura K, Takahashi J. Therapeutic application of stem cell technology toward the treatment of Parkinson\u2019s disease. Biol Pharm Bull. 2013;36:171\u20135.","journal-title":"Biol Pharm Bull"},{"key":"23_CR21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1186\/s40064-015-1400-1","volume":"4","author":"MH Fu","year":"2015","unstructured":"Fu MH, Li CL, Lin HL, Chen PC, Calkins MJ, Chang YF, et al. Stem cell transplantation therapy in Parkinson\u2019s disease. Springerplus. 2015;4:597.","journal-title":"Springerplus"},{"key":"23_CR22","doi-asserted-by":"crossref","first-page":"S312","DOI":"10.4103\/2152-7806.103024","volume":"3","author":"E Kocabicak","year":"2012","unstructured":"Kocabicak E, Tan SK, Temel Y. Deep brain stimulation of the subthalamic nucleus in Parkinson\u2019s disease: why so successful? Surg Neurol Int. 2012;3:S312\u20134.","journal-title":"Surg Neurol Int"},{"key":"23_CR23","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1161\/01.STR.0000255757.12198.0f","volume":"38","author":"HI Kornblum","year":"2007","unstructured":"Kornblum HI. Introduction to neural stem cells. Stroke. 2007;38:810\u20136.","journal-title":"Stroke"},{"key":"23_CR24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/exnr.2000.7426","volume":"164","author":"H Nishino","year":"2000","unstructured":"Nishino H, Hida H, Takei N, Kumazaki M, Nakajima K, Baba H. Mesencephalic neural stem (progenitor) cells develop to dopaminergic neurons more strongly in dopamine-depleted striatum than in intact striatum. Exp Neurol. 2000;164:209\u201314.","journal-title":"Exp Neurol"},{"key":"23_CR25","doi-asserted-by":"crossref","first-page":"12175","DOI":"10.1073\/pnas.0704091104","volume":"104","author":"DE Redmond","year":"2007","unstructured":"Redmond DE, Bjugstad KB, Teng YD, Ourednik V, Ourednik J, Wakeman DR, et al. Behavioral improvement in a primate Parkinson\u2019s model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci U S A. 2007;104:12175\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"23_CR26","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/brain\/123.7.1365","volume":"123","author":"CS Lee","year":"2000","unstructured":"Lee CS, Cenci MA, Schulzer M, Bj\u00f6rklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson\u2019s disease. Brain. 2000;123:1365\u201379.","journal-title":"Brain"},{"key":"23_CR27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0168-0102(94)00853-8","volume":"21","author":"T Kondoh","year":"1995","unstructured":"Kondoh T, Pundt LL, Low WC. Development of human fetal ventral mesencephalic grafts in rats with 6-OHDA lesions of the nigrostriatal pathway. Neurosci Res. 1995;21:223\u201333.","journal-title":"Neurosci Res"},{"key":"23_CR28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nbd.2007.08.008","volume":"29","author":"DE Redmond Jr","year":"2008","unstructured":"Redmond Jr DE, Vinuela A, Kordower JH, Isacson O. Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson\u2019s disease. Neurobiol Dis. 2008;29:103\u201316.","journal-title":"Neurobiol Dis"},{"key":"23_CR29","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.3389\/fncir.2016.00029","volume":"10","author":"H Yang","year":"2016","unstructured":"Yang H, Wang J, Wang F, Liu X, Chen H, Duan W, et al. Dopaminergic neuronal differentiation from the forebrain-derived human neural stem cells induced in cultures by using a combination of BMP-7 and Pramipexole with growth factors. Front Neural Circuits. 2016;10:1172.","journal-title":"Front Neural Circuits"},{"key":"23_CR30","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1096\/fj.06-6159fje","volume":"20","author":"CH Park","year":"2006","unstructured":"Park CH, Kang JS, Shin YH, Chang MY, Chung S, Koh HC, et al. Acquisition of in vitro and in vivo functionality of Nurr1-induced dopamine neurons. FASEB J. 2006;20:2553\u20135.","journal-title":"FASEB J"},{"key":"23_CR31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1172\/JCI32273","volume":"118","author":"CL Parish","year":"2008","unstructured":"Parish CL, Castelo-Branco G, Rawal N, Tonnesen J, Sorensen AT, Salto C, et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. J Clin Invest. 2008;118:149\u201360.","journal-title":"J Clin Invest"},{"key":"23_CR32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/2774","volume":"1","author":"L Studer","year":"1998","unstructured":"Studer L, Tabar V, McKay RD. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci. 1998;1:290\u20135.","journal-title":"Nat Neurosci"},{"key":"23_CR33","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/brain\/122.6.1121","volume":"122","author":"P Hagell","year":"1999","unstructured":"Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, et al. Sequential bilateral transplantation in Parkinson\u2019s disease. Brain. 1999;122:1121\u201332.","journal-title":"Brain"},{"key":"23_CR34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000099859","volume":"69","author":"M Levivier","year":"1998","unstructured":"Levivier M, Dethy S, Rodesch F, Peschanski M, Vandesteene A, David P, et al. Intracerebral transplantation of fetal ventral mesencephalon for patients with advanced Parkinson\u2019s disease. Stereotact Funct Neurosurg. 1998;69:99\u2013111.","journal-title":"Stereotact Funct Neurosurg"},{"key":"23_CR35","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJM199211263272202","volume":"327","author":"CR Freed","year":"1992","unstructured":"Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek E, Qi J, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson\u2019s disease. N Engl J Med. 1992;327:1549\u201355.","journal-title":"N Engl J Med"},{"key":"23_CR36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ana.410380307","volume":"38","author":"TB Freeman","year":"1995","unstructured":"Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson\u2019s disease. Ann Neurol. 1995;38:379\u201388.","journal-title":"Ann Neurol"},{"key":"23_CR37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ana.410350208","volume":"35","author":"O Lindvall","year":"1994","unstructured":"Lindvall O, Sawle G, Widner H, Rothwell JC, Bj\u00f6rklund A, Brooks D, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson\u2019s disease. Ann Neurol. 1994;35:172\u201380.","journal-title":"Ann Neurol"},{"key":"23_CR38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nm1752","volume":"14","author":"I Mendez","year":"2008","unstructured":"Mendez I, Vi\u00f1uela A, Astradsson A, Mukhida K, Hallett P, Robertson H, et al. Dopamine neurons implanted into people with Parkinson\u2019s disease survive without pathology for 14 years. Nat Med. 2008;14:507\u20139.","journal-title":"Nat Med"},{"key":"23_CR39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1749-6632.2009.05229.x","volume":"1184","author":"Y Chu","year":"2010","unstructured":"Chu Y, Kordower JH. Lewy body pathology in fetal grafts. Ann N Y Acad Sci. 2010;1184:55\u201367.","journal-title":"Ann N Y Acad Sci"},{"key":"23_CR40","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nn863","volume":"5","author":"P Hagell","year":"2002","unstructured":"Hagell P, Piccini P, Bj\u00f6rklund A, Brundin P, Rehncrona S, Widner H, et al. Dyskinesias following neural transplantation in Parkinson\u2019s disease. Nat Neurosci. 2002;5:627\u20138.","journal-title":"Nat Neurosci"},{"key":"23_CR41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","volume":"54","author":"CW Olanow","year":"2003","unstructured":"Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease. Ann Neurol. 2003;54:403\u201314.","journal-title":"Ann Neurol"},{"key":"23_CR42","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2005-11-011650","volume":"108","author":"AJ Nauta","year":"2006","unstructured":"Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EGA, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006;108:2114\u201320.","journal-title":"Blood"},{"key":"23_CR43","first-page":"1031","volume":"33","author":"DA Turner","year":"1993","unstructured":"Turner DA, Kearney W. Scientific and ethical concerns in neural fetal tissue transplantation. Neurosurgery. 1993;33:1031\u20137.","journal-title":"Neurosurgery"},{"key":"23_CR44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.celrep.2012.04.009","volume":"1","author":"A Kirkeby","year":"2012","unstructured":"Kirkeby A, Grealish S, Wolf DA, Nelander J, Wood J, Lundblad M, et al. Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep. 2012;1:703\u201314.","journal-title":"Cell Rep"},{"key":"23_CR45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/syn.20634","volume":"63","author":"S Muramatsu","year":"2009","unstructured":"Muramatsu S, Okuno T, Suzuki Y, Nakayama T, Kakiuchi T, Takino N, et al. Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson\u2019s disease. Synapse. 2009;63:541\u20138.","journal-title":"Synapse"},{"key":"23_CR46","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10648","volume":"480","author":"S Kriks","year":"2011","unstructured":"Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson\u2019s disease. Nature. 2011;480:547\u201351.","journal-title":"Nature"},{"key":"23_CR47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1172\/JCI21137","volume":"115","author":"Y Takagi","year":"2005","unstructured":"Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, Kishi Y, et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest. 2005;115:102\u20139.","journal-title":"J Clin Invest"},{"key":"23_CR48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JPD-2011-11070","volume":"1","author":"T Kikuchi","year":"2011","unstructured":"Kikuchi T, Morizane A, Doi D, Onoe H, Hayashi T, Kawasaki T, et al. Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson\u2019s disease. J Parkinsons Dis. 2011;1:395\u2013412.","journal-title":"J Parkinsons Dis"},{"key":"23_CR49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature20113","volume":"539","author":"S Falkner","year":"2016","unstructured":"Falkner S, Grade S, Dimou L, Conzelmann KK, Bonhoeffer T, G\u00f6tz M, et al. Transplanted embryonic neurons integrate into adult neocortical circuits. Nature. 2016;539:248\u201353.","journal-title":"Nature"},{"key":"23_CR50","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.stem.2014.09.017","volume":"15","author":"S Grealish","year":"2014","unstructured":"Grealish S, Diguet E, Kirkeby A, Mattsson B, Heuer A, Bramoulle Y, et al. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson\u2019s disease. Cell Stem Cell. 2014;15:653\u201365.","journal-title":"Cell Stem Cell"},{"key":"23_CR51","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1242\/dev.097394","volume":"142","author":"E Arenas","year":"2015","unstructured":"Arenas E, Denham M, Villaescusa JC. How to make a midbrain dopaminergic neuron. Development. 2015;142:1918\u201336.","journal-title":"Development"},{"key":"23_CR52","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1634\/stemcells.2005-0393","volume":"24","author":"A Brederlau","year":"2006","unstructured":"Brederlau A, Correia AS, Anisimov SV, Elmi M, Paul G, Roybon L, et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson\u2019s disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells. 2006;24:1433\u201340.","journal-title":"Stem Cells"},{"key":"23_CR53","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1634\/stemcells.2004-0094","volume":"22","author":"T Ben-Hur","year":"2004","unstructured":"Ben-Hur T, Idelson M, Khaner H, Pera M, Reinhartz E, Itzik A, et al. Transplantation of human embryonic stem cell\u2013derived neural progenitors improves behavioral deficit in parkinsonian rats. Stem Cells. 2004;22:1246\u201355.","journal-title":"Stem Cells"},{"key":"23_CR54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0065-230X(08)00005-5","volume":"100","author":"B Blum","year":"2008","unstructured":"Blum B, Benvenisty N. The Tumorigenicity of human embryonic stem cell. Adv Cancer Res. 2008;100:133\u201358.","journal-title":"Adv Cancer Res"},{"key":"23_CR55","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1472-6483(10)60663-3","volume":"13","author":"KH Grinnemo","year":"2006","unstructured":"Grinnemo KH, Kumagai-Braesch M, M\u00e2nsson-Broberg A, Skottman H, Hao X, Siddiqui A, et al. Human embryonic stem cells are immunogenic in allogeneic and xenogeneic settings. Reprod Biomed Online. 2006;13:712\u201324.","journal-title":"Reprod Biomed Online"},{"key":"23_CR56","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.stem.2015.06.007","volume":"17","author":"A Trounson","year":"2015","unstructured":"Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17:11\u201322.","journal-title":"Cell Stem Cell"},{"key":"23_CR57","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrm.2016.10","volume":"17","author":"A Trounson","year":"2016","unstructured":"Trounson A, DeWitt ND. Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol. 2016;17:194\u2013200.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"23_CR58","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3727\/096368915X687769","volume":"24","author":"R Gonzalez","year":"2015","unstructured":"Gonzalez R, Garitaonandia I, Crain A, Poustovoitov M, Abramihina T, Noskov A, et al. Proof of concept studies exploring the safety and functional activity of human parthenogenetic-derived neural stem cells for the treatment of Parkinson\u2019s disease. Cell Transplant. 2015;24:681\u201390.","journal-title":"Cell Transplant"},{"key":"23_CR59","volume-title":"Parkinson\u2019s stem cell therapy OK\u2019d for testing","author":"BJ Fikes","year":"2015","unstructured":"Fikes BJ. Parkinson\u2019s stem cell therapy OK\u2019d for testing. 2015. http:\/\/www.sandiegouniontribune.com\/business\/biotech\/sdut-international-stem-cell-parkinsons-australia-2015dec14-story.html . Accessed 20 Nov 2016."},{"key":"23_CR60","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.stem.2015.01.018","volume":"16","author":"PJ Hallett","year":"2015","unstructured":"Hallett PJ, Deleidi M, Astradsson A, Smith GA, Cooper O, Osborn TM, et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson\u2019s disease. Cell Stem Cell. 2015;16:269\u201374.","journal-title":"Cell Stem Cell"},{"key":"23_CR61","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nature10135","volume":"474","author":"T Zhao","year":"2011","unstructured":"Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474:212\u20135.","journal-title":"Nature"},{"key":"23_CR62","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jcyt.2015.02.001","volume":"17","author":"F Han","year":"2015","unstructured":"Han F, Wang W, Chen B, Chen C, Li S, Lu X, et al. Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson\u2019s disease. Cytotherapy. 2015;17:665\u201379.","journal-title":"Cytotherapy"},{"key":"23_CR63","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/stem.1415","volume":"31","author":"M Sundberg","year":"2013","unstructured":"Sundberg M, Bogetofte H, Lawson T, Jansson J, Smith G, Astradsson A, et al. Improved cell therapy protocols for Parkinson\u2019s disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells. 2013;31:1548\u201362.","journal-title":"Stem Cells"},{"key":"23_CR64","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1172\/JCI45794","volume":"121","author":"YH Rhee","year":"2011","unstructured":"Rhee YH, Ko JY, Chang MY, Yi SH, Kim D, Kim CH, et al. Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. J Clin Invest. 2011;121:2326\u201335.","journal-title":"J Clin Invest"},{"key":"23_CR65","doi-asserted-by":"crossref","first-page":"15921","DOI":"10.1073\/pnas.1010209107","volume":"107","author":"G Hargus","year":"2010","unstructured":"Hargus G, Cooper O, Deleidi M, Levy A, Lee K, Marlow E, et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in parkinsonian rats. Proc Natl Acad Sci U S A. 2010;107:15921\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"23_CR66","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.celrep.2013.02.016","volume":"3","author":"ME Emborg","year":"2013","unstructured":"Emborg ME, Liu Y, Xi J, Zhang X, Yin Y, Lu J, et al. Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain. Cell Rep. 2013;3:646\u201350.","journal-title":"Cell Rep"},{"key":"23_CR67","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature09342","volume":"467","author":"K Kim","year":"2010","unstructured":"Kim K, Doi A, Wen B, Ng K, Zhao R, Cahan P, et al. Epigenetic memory in induced pluripotent stem cells. Nature. 2010;467:285\u201390.","journal-title":"Nature"},{"key":"23_CR68","first-page":"109","volume":"8","author":"DS Kim","year":"2014","unstructured":"Kim DS, Ross PJ, Zaslavsky K, Ellis J. Optimizing neuronal differentiation from induced pluripotent stem cells to model ASD. Front Cell Neurosci. 2014;8:109.","journal-title":"Front Cell Neurosci"},{"key":"23_CR69","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1089\/scd.2009.1806.edi","volume":"18","author":"GC Parker","year":"2009","unstructured":"Parker GC, Acsadi G, Brenner CA. Mitochondria: determinants of stem cell fate? Stem Cells Dev. 2009;18:803\u20136.","journal-title":"Stem Cells Dev"},{"key":"23_CR70","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.stem.2016.04.015","volume":"19","author":"M Khacho","year":"2016","unstructured":"Khacho M, Clark A, Svoboda DS, Azzi J, MacLaurin JG, Meghaizel C, et al. Mitochondrial dynamics impacts stem cell identity and fate decisions by regulating a nuclear transcriptional program. Cell Stem Cell. 2016;19:232\u201347.","journal-title":"Cell Stem Cell"},{"key":"23_CR71","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cell.2011.06.019","volume":"146","author":"F Soldner","year":"2011","unstructured":"Soldner F, Laganiere J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell. 2011;146:318\u201331.","journal-title":"Cell"},{"key":"23_CR72","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1093\/hmg\/ddu204","volume":"23","author":"CA Ross","year":"2014","unstructured":"Ross CA, Akimov SS. Human-induced pluripotent stem cells: potential for neurodegenerative diseases. Hum Mol Genet. 2014;23:R17\u201326.","journal-title":"Hum Mol Genet"},{"key":"23_CR73","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/mt.2016.10","volume":"24","author":"ML Maeder","year":"2016","unstructured":"Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Mol Ther. 2016;24:430\u201346.","journal-title":"Mol Ther"},{"key":"23_CR74","doi-asserted-by":"crossref","first-page":"15015","DOI":"10.1038\/celldisc.2015.15","volume":"1","author":"L Wang","year":"2015","unstructured":"Wang L, Cao J, Wang Y, Lan T, Liu L, Wang W, et al. Immunogenicity and functional evaluation of iPSC-derived organs for transplantation. Cell Discov. 2015;1:15015.","journal-title":"Cell Discov"},{"doi-asserted-by":"crossref","unstructured":"Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sundberg M, et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson\u2019s disease. Sci Transl Med. 2012;4:141ra90\u20130.","key":"23_CR75","DOI":"10.1126\/scitranslmed.3003985"},{"key":"23_CR76","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.stem.2011.01.013","volume":"8","author":"HN Nguyen","year":"2011","unstructured":"Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell. 2011;8:267\u201380.","journal-title":"Cell Stem Cell"},{"key":"23_CR77","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncomms1669","volume":"3","author":"H Jiang","year":"2012","unstructured":"Jiang H, Ren Y, Yuen EY, Zhong P, Ghaedi M, Hu Z, et al. Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat Commun. 2012;3:668.","journal-title":"Nat Commun"},{"key":"23_CR78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37\u201352.","journal-title":"Cell"},{"key":"23_CR79","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ncomms1453","volume":"2","author":"MJ Devine","year":"2011","unstructured":"Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, et al. Parkinson\u2019s disease induced pluripotent stem cells with triplication of the \u03b1-synuclein locus. Nat Commun. 2011;2:440.","journal-title":"Nat Commun"},{"key":"23_CR80","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.stem.2013.01.008","volume":"12","author":"P Reinhardt","year":"2013","unstructured":"Reinhardt P, Schmid B, Burbulla LF, Sch\u00f6ndorf DC, Wagner L, Glatza M, et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell. 2013;12:354\u201367.","journal-title":"Cell Stem Cell"},{"key":"23_CR81","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.celrep.2014.10.023","volume":"9","author":"CM Woodard","year":"2014","unstructured":"Woodard CM, Campos BA, Kuo SH, Nirenberg MJ, Nestor MW, Zimmer M, et al. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson\u2019s disease. Cell Rep. 2014;9:1173\u201382.","journal-title":"Cell Rep"},{"key":"23_CR82","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/emmm.201200215","volume":"4","author":"A S\u00e1nchez-Dan\u00e9s","year":"2012","unstructured":"S\u00e1nchez-Dan\u00e9s A, Richaud-Patin Y, Carballo-Carbajal I, Jim\u00e9nez-Delgado S, Caig C, Mora S, et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson\u2019s disease. EMBO Mol Med. 2012;4:380\u201395.","journal-title":"EMBO Mol Med"},{"key":"23_CR83","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.15252\/emmm.201505439","volume":"7","author":"R Fern\u00e1ndez-Santiago","year":"2015","unstructured":"Fern\u00e1ndez-Santiago R, Carballo-Carbajal I, Castellano G, Torrent R, Richaud Y, S\u00e1nchez-Dan\u00e9s A, et al. Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson\u2019s disease patients. EMBO Mol Med. 2015;7:1529\u201346.","journal-title":"EMBO Mol Med"},{"key":"23_CR84","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1093\/hmg\/ddr394","volume":"20","author":"T Yagi","year":"2011","unstructured":"Yagi T, Ito D, Okada Y, Akamatsu W, Nihei Y, Yoshizaki T, et al. Modeling familial Alzheimer\u2019s disease with induced pluripotent stem cells. Hum Mol Genet. 2011;20:4530\u20139.","journal-title":"Hum Mol Genet"},{"key":"23_CR85","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3233\/JAD-121984","volume":"34","author":"U Wojda","year":"2013","unstructured":"Wojda U, Kuznicki J. Alzheimer\u2019s disease modeling: ups, downs, and perspectives for human induced pluripotent stem cells. J Alzheimers Dis. 2013;34:563\u201388.","journal-title":"J Alzheimers Dis"},{"key":"23_CR86","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/0891988710383571","volume":"23","author":"LM Bekris","year":"2010","unstructured":"Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23:213\u201327.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"23_CR87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/alzrt155","volume":"5","author":"B Lam","year":"2013","unstructured":"Lam B, Masellis M, Freedman M, Stuss DT, Black SE. Clinical, imaging, and pathological heterogeneity of the Alzheimer\u2019s disease syndrome. Alzheimers Res Ther. 2013;5:1.","journal-title":"Alzheimers Res Ther"},{"key":"23_CR88","doi-asserted-by":"crossref","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"23_CR89","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13024-016-0106-3","volume":"11","author":"J Yang","year":"2016","unstructured":"Yang J, Li S, He XB, Cheng C, Le W. Induced pluripotent stem cells in Alzheimer\u2019s disease: applications for disease modeling and cell-replacement therapy. Mol Neurodegener. 2016;11:39.","journal-title":"Mol Neurodegener"},{"key":"23_CR90","doi-asserted-by":"publisher","DOI":"10.2016\/j.brainres.2015.10.005","author":"SE Sullivan","year":"2015","unstructured":"Sullivan SE, Young-Pearse TL. Induced pluripotent stem cells as a discovery tool for Alzheimers disease. Brain Res. 2015; doi: 10.2016\/j.brainres.2015.10.005 .","journal-title":"Brain Res"},{"key":"23_CR91","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/embj.201387098","volume":"33","author":"H Inoue","year":"2014","unstructured":"Inoue H, Nagata N, Kurokawa H, Yamanaka S. iPS cells: a game changer for future medicine. EMBO J. 2014;33:409\u201317.","journal-title":"EMBO J"},{"key":"23_CR92","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mam.2015.06.007","volume":"43\u201344","author":"AA Sproul","year":"2015","unstructured":"Sproul AA. Being human: the role of pluripotent stem cells in regenerative medicine and humanizing Alzheimer\u2019s disease models. Mol Asp Med. 2015;43\u201344:54\u201365.","journal-title":"Mol Asp Med"},{"key":"23_CR93","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4252\/wjsc.v6.i2.239","volume":"6","author":"L Mohamet","year":"2014","unstructured":"Mohamet L, Miazga NJ, Ward CM. Familial Alzheimer\u2019s disease modelling using induced pluripotent stem cell technology. World J Stem Cells. 2014;6:239\u201347.","journal-title":"World J Stem Cells"},{"key":"23_CR94","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/alzrt107","volume":"4","author":"S Weggen","year":"2012","unstructured":"Weggen S, Beher D. Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer\u2019s disease. Alzheimers Res Ther. 2012;4:9.","journal-title":"Alzheimers Res Ther"},{"doi-asserted-by":"crossref","unstructured":"Shi Y, Kirwan P, Smith J, MacLean G, Orkin SH, Livesey FJ. A human stem cell model of early Alzheimer\u2019s disease pathology in Down syndrome. Sci Transl Med. 2012;4:124ra9.","key":"23_CR95","DOI":"10.1126\/scitranslmed.3003771"},{"unstructured":"Prasher VP. Down syndrome and Alzheimer\u2019s disease: biological correlates: Radcliffe Publishing; 2006.","key":"23_CR96"},{"key":"23_CR97","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature10821","volume":"482","author":"MA Israel","year":"2012","unstructured":"Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, et al. Probing sporadic and familial Alzheimer\u2019s disease using induced pluripotent stem cells. Nature. 2012;482:216\u201320.","journal-title":"Nature"},{"key":"23_CR98","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ana.1254","volume":"50","author":"A Cataldo","year":"2001","unstructured":"Cataldo A, Rebeck GW, Ghetri B, Hulette C, Lippa C, Van Broeckhoven C, et al. Endocytic disturbances distinguish among subtypes of Alzheimer\u2019s disease and related disorders. Ann Neurol. 2001;50:661\u20135.","journal-title":"Ann Neurol"},{"key":"23_CR99","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.stem.2013.01.009","volume":"12","author":"T Kondo","year":"2013","unstructured":"Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, et al. Modeling Alzheimer\u2019s disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell. 2013;12:487\u201396.","journal-title":"Cell Stem Cell"},{"key":"23_CR100","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1093\/hmg\/ddu064","volume":"23","author":"CR Muratore","year":"2014","unstructured":"Muratore CR, Rice HC, Srikanth P, Callahan DG, Shin T, Benjamin LN, et al. The familial Alzheimer\u2019s disease APPV717I mutation alters APP processing and tau expression in iPSC-derived neurons. Hum Mol Genet. 2014;23:3523\u201336.","journal-title":"Hum Mol Genet"},{"key":"23_CR101","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med. 1996;2:864\u201370.","journal-title":"Nat Med"},{"key":"23_CR102","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0896-6273(00)80230-5","volume":"17","author":"DR Borchelt","year":"1996","unstructured":"Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al. Familial Alzheimer\u2019s disease\u2013linked presenilin 1 variants elevate A\u03b21\u201342\/1\u201340 ratio in vitro and in vivo. Neuron. 1996;17:1005\u201313.","journal-title":"Neuron"},{"key":"23_CR103","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1073\/pnas.94.5.2025","volume":"94","author":"T Tomita","year":"1997","unstructured":"Tomita T, Maruyama K, Saido TC, Kume H, Shinozaki K, Tokuhiro S, et al. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid \u03b2 protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci U S A. 1997;94:2025\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"23_CR104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084547","volume":"9","author":"AA Sproul","year":"2014","unstructured":"Sproul AA, Jacob S, Pre D, Kim SH, Nestor MW, Navarro-Sobrino M, et al. Characterization and molecular profiling of PSEN1 familial Alzheimer\u2019s disease iPSC-derived neural progenitors. PLoS One. 2014;9:e84547.","journal-title":"PLoS One"},{"key":"23_CR105","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.celrep.2015.03.068","volume":"11","author":"S Moore","year":"2015","unstructured":"Moore S, Evans LD, Andersson T, Portelius E, Smith J, Dias TB, et al. APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell Rep. 2015;11:689\u201396.","journal-title":"Cell Rep"},{"key":"23_CR106","doi-asserted-by":"crossref","first-page":"R82","DOI":"10.1093\/hmg\/dds319","volume":"21","author":"JE Young","year":"2012","unstructured":"Young JE, Goldstein LSB. Alzheimer\u2019s disease in a dish: promises and challenges of human stem cell models. Hum Mol Genet. 2012;21:R82\u20139.","journal-title":"Hum Mol Genet"},{"key":"23_CR107","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.celrep.2013.10.018","volume":"5","author":"G Woodruff","year":"2013","unstructured":"Woodruff G, Young JE, Martinez FJ, Buen F, Gore A, Kinaga J, et al. The presenilin-1 \u0394E9 mutation results in reduced \u03b3-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. Cell Rep. 2013;5:974\u201385.","journal-title":"Cell Rep"},{"key":"23_CR108","doi-asserted-by":"crossref","first-page":"a006296","DOI":"10.1101\/cshperspect.a006296","volume":"2","author":"RE Tanzi","year":"2012","unstructured":"Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2:a006296.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"23_CR109","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/archpsyc.63.2.168","volume":"63","author":"M Gatz","year":"2006","unstructured":"Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168\u201374.","journal-title":"Arch Gen Psychiatry"},{"key":"23_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2016.242","author":"R Delgado-Morales","year":"2017","unstructured":"Delgado-Morales R, Esteller M. Opening up the DNA methylome of dementia. Mol Psychiatry. 2017; doi: 10.1038\/mp.2016.242 .","journal-title":"Mol Psychiatry"},{"key":"23_CR111","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fgene.2014.00369","volume":"5","author":"J Lord","year":"2014","unstructured":"Lord J, Lu AJ, Cruchaga C. Identification of rare variants in Alzheimer\u2019s disease. Front Genet. 2014;5:369.","journal-title":"Front Genet"},{"key":"23_CR112","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/gim.2015.117","volume":"18","author":"C Van Cauwenberghe","year":"2016","unstructured":"Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18:421\u201330.","journal-title":"Genet Med"},{"doi-asserted-by":"crossref","unstructured":"Iatrou A, Kenis G, Rutten BPF, Lunnon K, van den Hove DLA. Epigenetic dysregulation of brainstem nuclei in the pathogenesis of Alzheimer\u2019s disease: looking in the correct place at the right time? Cell Mol Life Sci. 2016;1\u201315","key":"23_CR113","DOI":"10.1007\/s00018-016-2361-4"},{"key":"23_CR114","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1326-9-3","volume":"9","author":"L Duan","year":"2014","unstructured":"Duan L, Bhattacharyya BJ, Belmadani A, Pan L, Miller RJ, Kessler JA. Stem cell derived basal forebrain cholinergic neurons from Alzheimer\u2019s disease patients are more susceptible to cell death. Mol Neurodegener. 2014;9:3.","journal-title":"Mol Neurodegener"},{"key":"23_CR115","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.stem.2015.02.004","volume":"16","author":"JE Young","year":"2015","unstructured":"Young JE, Boulanger-Weill J, Williams DA, Woodruff G, Buen F, Revilla AC, et al. Elucidating molecular phenotypes caused by the SORL1 Alzheimer\u2019s disease genetic risk factor using human induced pluripotent stem cells. Cell Stem Cell. 2015;16:373\u201385.","journal-title":"Cell Stem Cell"},{"key":"23_CR116","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/postgradmedj-2011-130363","volume":"88","author":"K Alagiakrishnan","year":"2012","unstructured":"Alagiakrishnan K, Gill SS, Fagarasanu A. Genetics and epigenetics of Alzheimer\u2019s disease. Postgrad Med J. 2012;88:522\u20139.","journal-title":"Postgrad Med J"},{"key":"23_CR117","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/nan.12101","volume":"40","author":"C Medway","year":"2014","unstructured":"Medway C, Morgan K. The genetics of Alzheimer\u2019s disease; putting flesh on the bones. Neuropathol Appl Neurobiol. 2014;40:97\u2013105.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"23_CR118","doi-asserted-by":"crossref","first-page":"13461","DOI":"10.1073\/pnas.0503689102","volume":"102","author":"OM Andersen","year":"2005","unstructured":"Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, et al. Neuronal sorting protein-related receptor sorLA\/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005;102:13461\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"23_CR119","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/01.jnen.0000228205.19915.20","volume":"65","author":"SE Dodson","year":"2006","unstructured":"Dodson SE, Gearing M, Lippa CF, Montine TJ, Levey AI, Lah JJ. LR11\/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol. 2006;65:866\u201372.","journal-title":"J Neuropathol Exp Neurol"},{"key":"23_CR120","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12864-015-1262-5","volume":"16","author":"AM Hossini","year":"2015","unstructured":"Hossini AM, Megges M, Prigione A, Lichtner B, Toliat MR, Wruck W, et al. Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer\u2019s disease donor as a model for investigating AD-associated gene regulatory networks. BMC Genomics. 2015;16:84.","journal-title":"BMC Genomics"},{"key":"23_CR121","first-page":"1299","volume":"86","author":"W Xu","year":"2015","unstructured":"Xu W, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. Meta-analysis of modifiable risk factors for Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2015;86:1299\u2013306.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"23_CR122","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tig.2015.12.001","volume":"32","author":"G Kungulovski","year":"2016","unstructured":"Kungulovski G, Jeltsch A. Epigenome editing: state of the art, concepts, and perspectives. Trends Genet. 2016;32:101\u201313.","journal-title":"Trends Genet"},{"key":"23_CR123","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nmeth.3733","volume":"13","author":"PI Thakore","year":"2016","unstructured":"Thakore PI, Black JB, Hilton IB, Gersbach CA. Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat Methods. 2016;13:127\u201337.","journal-title":"Nat Methods"},{"key":"23_CR124","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00126839-200607020-00003","volume":"7","author":"DM Barten","year":"2006","unstructured":"Barten DM, Meredith Jr JE, Zaczek R, Houston JG, Albright CF. Gamma-secretase inhibitors for Alzheimer\u2019s disease: balancing efficacy and toxicity. Drugs R D. 2006;7:87\u201397.","journal-title":"Drugs R D"},{"key":"23_CR125","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1039\/C3CS60460H","volume":"43","author":"AK Ghosh","year":"2014","unstructured":"Ghosh AK, Osswald HL. BACE1 (beta-secretase) inhibitors for the treatment of Alzheimer\u2019s disease. Chem Soc Rev. 2014;43:6765\u2013813.","journal-title":"Chem Soc Rev"},{"key":"23_CR126","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1756285612461679","volume":"6","author":"KG Yiannopoulou","year":"2013","unstructured":"Yiannopoulou KG, Papageorgiou SG. Current and future treatments for Alzheimer\u2019s disease. Ther Adv Neurol Disord. 2013;6:19\u201333.","journal-title":"Ther Adv Neurol Disord"},{"key":"23_CR127","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5582\/irdr.2014.01022","volume":"3","author":"R Lozano","year":"2014","unstructured":"Lozano R, Rosero CA, Hagerman RJ. Fragile X spectrum disorders. Intractable Rare Dis Res. 2014;3:134\u201346.","journal-title":"Intractable Rare Dis Res"},{"key":"23_CR128","doi-asserted-by":"crossref","first-page":"190","DOI":"10.25100\/cm.v45i4.1810","volume":"45","author":"W Saldarriaga","year":"2014","unstructured":"Saldarriaga W, Tassone F, Gonz\u00e1lez-Teshima LY, Forero-Forero JV, Ayala-Zapata S, Hagerman R. Fragile X syndrome. Colomb Med. 2014;45:190\u20138.","journal-title":"Colomb Med"},{"key":"23_CR129","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/hmg\/5.8.1083","volume":"5","author":"DE Eberhart","year":"1996","unstructured":"Eberhart DE, Malter HE, Feng Y, Warren ST. The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet. 1996;5:1083\u201391.","journal-title":"Hum Mol Genet"},{"key":"23_CR130","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.7692601","volume":"262","author":"CT Ashley","year":"1993","unstructured":"Ashley CT, Wilkinson KD, Reines D, Warren ST. FMR1 protein: conserved RNP family domains and selective RNA binding. Science. 1993;262:563\u20136.","journal-title":"Science"},{"key":"23_CR131","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1523\/JNEUROSCI.0099-04.2004","volume":"24","author":"LN Antar","year":"2004","unstructured":"Antar LN, Afroz R, Dictenberg JB, Carroll RC, Bassell GJ. Metabotropic glutamate receptor activation regulates fragile X mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J Neurosci. 2004;24:2648\u201355.","journal-title":"J Neurosci"},{"key":"23_CR132","first-page":"17","volume":"7","author":"JAC Broek","year":"2016","unstructured":"Broek JAC. Lin Z, de Gruiter HM, van \u2018t Spijker H, Haasdijk ED, cox D, et al. Synaptic vesicle dynamic changes in a model of fragile X Mol Autism. 2016;7:17.","journal-title":"Synaptic vesicle dynamic changes in a model of fragile X Mol Autism"},{"key":"23_CR133","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1126\/science.1675488","volume":"252","author":"EJ Kremer","year":"1991","unstructured":"Kremer EJ, Pritchard M, Lynch M, Yu S, Holman K, Baker E, et al. Mapping of DNA instability at the fragile-X to a Trinucleotide repeat sequence P(Ccg)N. Science. 1991;252:1711\u20134.","journal-title":"Science"},{"key":"23_CR134","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/1.6.397","volume":"1","author":"JS Sutcliffe","year":"1992","unstructured":"Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, et al. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet. 1992;1:397\u2013400.","journal-title":"Hum Mol Genet"},{"key":"23_CR135","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3389\/fgene.2014.00309","volume":"5","author":"MR Mailick","year":"2014","unstructured":"Mailick MR, Hong J, Rathouz P, Baker MW, Greenberg JS, Smith L, et al. Low-normal FMR1 CGG repeat length: phenotypic associations. Front Genet. 2014;5:309.","journal-title":"Front Genet"},{"key":"23_CR136","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0896-6273(03)00034-5","volume":"37","author":"KY Miyashiro","year":"2003","unstructured":"Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu L, et al. RNA cargoes associating with in cellular functioning in Fmrl Fmr1 reveal deficits null mice. Neuron. 2003;37:417\u201331.","journal-title":"Neuron"},{"key":"23_CR137","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1017\/S1355838202020642","volume":"8","author":"B Primerano","year":"2002","unstructured":"Primerano B, Tassone F, Hagerman RJ, Hagerman P, Amaldi F, Bagni C. Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA. 2002;8:1482\u20138.","journal-title":"RNA"},{"key":"23_CR138","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4137\/JEN.S25524","volume":"9","author":"JA Suhl","year":"2015","unstructured":"Suhl JA, Warren ST. Single-nucleotide mutations in FMR1 reveal novel functions and regulatory mechanisms of the fragile X syndrome protein FMRP. J Exp Neurosci. 2015;9:35\u201341.","journal-title":"J Exp Neurosci"},{"key":"23_CR139","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.yexcr.2006.10.002","volume":"313","author":"JR Brouwer","year":"2007","unstructured":"Brouwer JR, Mientjes EJ, Bakker CE, Nieuwenhuizen IM, Severijnen LA, Van der Linde HC, et al. Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated fragile X full mutation. Exp Cell Res. 2007;313:244\u201353.","journal-title":"Exp Cell Res"},{"key":"23_CR140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/genes7100077","volume":"7","author":"H Mor-Shaked","year":"2016","unstructured":"Mor-Shaked H, Eiges R. Modeling fragile X syndrome using human pluripotent stem cells. Genes (Basel). 2016;7:77.","journal-title":"Genes (Basel)"},{"key":"23_CR141","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.stem.2010.04.005","volume":"6","author":"A Urbach","year":"2010","unstructured":"Urbach A, Bar-Nur O, Daley GQ, Benvenisty N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell. 2010;6:407\u201311.","journal-title":"Cell Stem Cell"},{"key":"23_CR142","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2505","author":"O Khalfallah","year":"2016","unstructured":"Khalfallah O, Jarjat M, Davidovic L, Nottet N, Cest\u00e8le S, Mantegazza M, et al. Depletion of the fragile X mental retardation protein in embryonic stem cells alters the kinetics of neurogenesis. Stem Cells. 2016; doi: 10.1002\/stem.2505 .","journal-title":"Stem Cells"},{"key":"23_CR143","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/dgd.12280","volume":"58","author":"L Ben-Reuven","year":"2016","unstructured":"Ben-Reuven L, Reiner O. Modeling the autistic cell: iPSCs recapitulate developmental principles of syndromic and nonsyndromic ASD. Develop Growth Differ. 2016;58:481\u201391.","journal-title":"Develop Growth Differ"},{"key":"23_CR144","volume":"6","author":"SD Sheridan","year":"2011","unstructured":"Sheridan SD, Theriault KM, Reis SA, Zhou F, Madison JM, Daheron L, et al. Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome. PLoS One. 2011;6:e26203.","journal-title":"PLoS One"},{"key":"23_CR145","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1089\/scd.2014.0030","volume":"23","author":"ME Doers","year":"2014","unstructured":"Doers ME, Musser MT, Nichol R, Berndt ER, Baker M, Gomez TM, et al. iPSC-derived forebrain neurons from FXS individuals show defects in initial Neurite outgrowth. Stem Cells Dev. 2014;23:1777\u201387.","journal-title":"Stem Cells Dev"},{"key":"23_CR146","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fgene.2015.00192","volume":"6","author":"K Usdin","year":"2015","unstructured":"Usdin K, Kumari D. Repeat-mediated epigenetic dysregulation of the FMR1 gene in the fragile X-related disorders. Front Genet. 2015;6:192.","journal-title":"Front Genet"},{"key":"23_CR147","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1093\/hmg\/dds207","volume":"21","author":"J Liu","year":"2012","unstructured":"Liu J, Ko\u015bcielska KA, Cao Z, Hulsizer S, Grace N, Mitchell G, et al. Signaling defects in iPSC-derived fragile X premutation neurons. Hum Mol Genet. 2012;21:3795\u2013805.","journal-title":"Hum Mol Genet"},{"key":"23_CR148","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.stemcr.2014.07.013","volume":"3","author":"CEF Esch de","year":"2014","unstructured":"de Esch CEF, Ghazvini M, Loos F, Schelling-Kazaryan N, Widagdo W, Munshi ST, et al. Epigenetic characterization of the FMR1 promoter in induced pluripotent stem cells from human fibroblasts carrying an unmethylated full mutation. Stem Cell Rep. 2014;3:548\u201355.","journal-title":"Stem Cell Rep"},{"key":"23_CR149","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.celrep.2015.08.084","volume":"13","author":"CY Park","year":"2015","unstructured":"Park CY, Halevy T, Lee DR, Sung JJ, Lee JS, Yanuka O, et al. Reversion of FMR1 methylation and silencing by editing the triplet repeats in fragile X iPSC-derived neurons. Cell Rep. 2015;13:234\u201341.","journal-title":"Cell Rep"},{"key":"23_CR150","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"},{"key":"23_CR151","doi-asserted-by":"crossref","first-page":"800","DOI":"10.5966\/sctm.2014-0278","volume":"4","author":"D Kumari","year":"2015","unstructured":"Kumari D, Swaroop M, Southall N, Huang W, Zheng W, Usdin K. High-throughput screening to identify compounds that increase fragile X mental retardation protein expression in neural stem cells differentiated from fragile X syndrome patient-derived induced pluripotent stem cells. Stem Cells Transl Med. 2015;4:800\u20138.","journal-title":"Stem Cells Transl Med"},{"key":"23_CR152","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1469-8749.1965.tb07844.x","volume":"7","author":"H Angelman","year":"1965","unstructured":"Angelman H. \u201cPuppet\u201d children a report on three cases. Dev Med Child Neurol. 1965;7:681\u20138.","journal-title":"Dev Med Child Neurol"},{"key":"23_CR153","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/ejhg.2009.67","volume":"17","author":"G Van Buggenhout","year":"2009","unstructured":"Van Buggenhout G, Fryns JP. Angelman syndrome (AS, MIM 105830). Eur J Hum Genet. 2009;17:1367\u201373.","journal-title":"Eur J Hum Genet"},{"key":"23_CR154","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1362361304042720","volume":"8","author":"A Trillingsgaard","year":"2004","unstructured":"Trillingsgaard A, \u00d8Stergaard JR. Autism in Angelman syndrome: an exploration of comorbidity. Autism. 2004;8:163\u201374.","journal-title":"Autism"},{"key":"23_CR155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/ejhg.2008.165","volume":"17","author":"SB Cassidy","year":"2009","unstructured":"Cassidy SB, Driscoll DJ. Prader-Willi syndrome. Eur J Hum Genet. 2009;17:3\u201313.","journal-title":"Eur J Hum Genet"},{"key":"23_CR156","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.pcl.2015.03.004","volume":"62","author":"L Kalsner","year":"2015","unstructured":"Kalsner L, Chamberlain SJ. Prader-Willi, Angelman, and 15q11-q13 duplication syndromes. Pediatr Clin N Am. 2015;62:587\u2013606.","journal-title":"Pediatr Clin N Am"},{"key":"23_CR157","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.gde.2010.01.009","volume":"20","author":"MV Koerner","year":"2010","unstructured":"Koerner MV, Barlow DP. Genomic imprinting - an epigenetic gene-regulatory model. Curr Opin Genet Dev. 2010;20:164\u201370.","journal-title":"Curr Opin Genet Dev"},{"key":"23_CR158","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006427","volume":"12","author":"M Sanchez-Delgado","year":"2016","unstructured":"Sanchez-Delgado M, Court F, Vidal E, Medrano J, Monteagudo-S\u00e1nchez A, Martin-Trujillo A, et al. Human oocyte-derived methylation differences persist in the placenta revealing widespread transient imprinting. PLoS Genet. 2016;12:e1006427.","journal-title":"PLoS Genet"},{"key":"23_CR159","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/nrn2235","volume":"8","author":"LS Wilkinson","year":"2007","unstructured":"Wilkinson LS, Davies W, Isles AR. Genomic imprinting effects on brain development and function. Nat Rev Neurosci. 2007;8:832\u201343.","journal-title":"Nat Rev Neurosci"},{"key":"23_CR160","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/ajmg.a.32364","volume":"146A","author":"B Horsthemke","year":"2008","unstructured":"Horsthemke B, Wagstaff J. Mechanisms of imprinting of the Prader-Willi\/Angelman region. Am J Med Genet. 2008;146A:2041\u201352.","journal-title":"Am J Med Genet"},{"key":"23_CR161","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1101\/gr.8.9.881","volume":"8","author":"M Const\u00e2ncia","year":"1998","unstructured":"Const\u00e2ncia M, Pickard B, Kelsey G, Reik W. Imprinting mechanisms. Genome Res. 1998;8:881\u2013900.","journal-title":"Genome Res"},{"issue":"3","key":"23_CR162","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2174\/138920211795677877","volume":"12","author":"MG Butler","year":"2011","unstructured":"Butler MG. Prader-Willi syndrome: obesity due to genomic imprinting. Curr Genomics. 2011;12(3):204\u201315.","journal-title":"Curr Genomics"},{"key":"23_CR163","doi-asserted-by":"crossref","first-page":"14311","DOI":"10.1073\/pnas.250426397","volume":"97","author":"J Cavaill\u00e9","year":"2000","unstructured":"Cavaill\u00e9 J, Buiting K, Kiefmann M, Lalande M, Brannan CI, Horsthemke B, et al. Identification of brain-specific and imprinted small nucleolar RNA genes exhibiting an unusual genomic organization. Proc Natl Acad Sci U S A. 2000;97:14311\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"23_CR164","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.tig.2016.05.001","volume":"32","author":"M Sanchez-Delgado","year":"2016","unstructured":"Sanchez-Delgado M, Riccio A, Eggermann T, Maher ER, Lapunzina P, Mackay D, et al. Causes and consequences of multi-locus imprinting disturbances in humans. Trends Genet. 2016;32:444\u201355.","journal-title":"Trends Genet"},{"key":"23_CR165","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2217\/epi.15.70","volume":"7","author":"JM LaSalle","year":"2015","unstructured":"LaSalle JM, Reiter LT, Chamberlain SJ. Epigenetic regulation of UBE3A and roles in human neurodevelopmental disorders. Epigenomics. 2015;7:1213\u201328.","journal-title":"Epigenomics"},{"key":"23_CR166","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.neuroscience.2015.12.040","volume":"321","author":"SW Hulbert","year":"2016","unstructured":"Hulbert SW, Jiang YH. Monogenic mouse models of autism spectrum disorders: common mechanisms and missing links. Neuroscience. 2016;321:3\u201323.","journal-title":"Neuroscience"},{"key":"23_CR167","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0896-6273(00)80596-6","volume":"21","author":"YH Jiang","year":"1998","unstructured":"Jiang YH, Armstrong D, Albrecht U, Atkins CM, Noebels JL, Eichele G, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron. 1998;21:799\u2013811.","journal-title":"Neuron"},{"key":"23_CR168","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/468907a","volume":"468","author":"P Scheiffele","year":"2010","unstructured":"Scheiffele P, Beg AA. Neuroscience: Angelman syndrome connections. Nature. 2010;468:907\u20138.","journal-title":"Nature"},{"key":"23_CR169","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2010.01.026","volume":"140","author":"PL Greer","year":"2010","unstructured":"Greer PL, Hanayama R, Bloodgood BL, Mardinly AR, Lipton DM, Flavell SW, et al. The Angelman syndrome protein Ube3A regulates synapse development by Ubiquitinating arc. Cell. 2010;140:704\u201316.","journal-title":"Cell"},{"key":"23_CR170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.yfrne.2013.01.002","volume":"34","author":"S Bervini","year":"2013","unstructured":"Bervini S, Herzog H. Mouse models of Prader\u2013Willi syndrome: a systematic review. Front Neuroendocrinol. 2013;34:107\u201319.","journal-title":"Front Neuroendocrinol"},{"key":"23_CR171","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajmg.a.36416","volume":"164","author":"WH Tan","year":"2014","unstructured":"Tan WH, Bird LM, Thibert RL, Williams CA. If not Angelman, what is it? A review of Angelman-like syndromes. Am J Med Genet A. 2014;164:975\u201392.","journal-title":"Am J Med Genet A"},{"key":"23_CR172","doi-asserted-by":"crossref","first-page":"40303","DOI":"10.1074\/jbc.M110.183392","volume":"285","author":"J Yang","year":"2010","unstructured":"Yang J, Cai J, Zhang Y, Wang X, Li W, Xu J, et al. Induced pluripotent stem cells can be used to model the genomic imprinting disorder Prader-Willi syndrome. J Biol Chem. 2010;285:40303\u201311.","journal-title":"J Biol Chem"},{"key":"23_CR173","doi-asserted-by":"crossref","first-page":"17668","DOI":"10.1073\/pnas.1004487107","volume":"107","author":"SJ Chamberlain","year":"2010","unstructured":"Chamberlain SJ, Chen PF, Ng KY, Bourgois-Rocha F, Lemtiri-Chlieh F, Levine ES, et al. Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader \u2013 Willi syndromes. Proc Natl Acad Sci U S A. 2010;107:17668\u201373.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"23_CR174","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/2040-2392-5-44","volume":"5","author":"ND Germain","year":"2014","unstructured":"Germain ND, Chen PF, Plocik AM, Glatt-Deeley H, Brown J, Fink JJ, et al. Gene expression analysis of human induced pluripotent stem cell-derived neurons carrying copy number variants of chromosome 15q11-q13.1. Mol Autism. 2014;5:44.","journal-title":"Mol Autism"},{"key":"23_CR175","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/ng0598-15","volume":"19","author":"C Rougeulle","year":"1998","unstructured":"Rougeulle C, Cardoso C, Font\u00e9s M, Colleaux L, Lalande M. An imprinted antisense RNA overlaps UBE3A and a second maternally expressed transcript. Nat Genet. 1998;19:15\u20136.","journal-title":"Nat Genet"},{"key":"23_CR176","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/ng0997-12","volume":"17","author":"TH Vu","year":"1997","unstructured":"Vu TH, Hoffman AR. Imprinting of the Angelman syndrome gene, UBE3A, is restricted to brain. Nat Genet. 1997;17:12\u20133.","journal-title":"Nat Genet"},{"key":"23_CR177","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/hmg\/ddt628","volume":"23","author":"K Martins-Taylor","year":"2014","unstructured":"Martins-Taylor K, Hsiao JS, Chen PF, Glatt-Deeley H, De Smith AJ, Blakemore AIF, et al. Imprinted expression of UBE3A in non-neuronal cells from a Prader-willi syndrome patient with an atypical deletion. Hum Mol Genet. 2014;23:2364\u201373.","journal-title":"Hum Mol Genet"},{"key":"23_CR178","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/7651_2014_169","volume":"1353","author":"SJ Chamberlain","year":"2016","unstructured":"Chamberlain SJ, Germain ND, Chen PF, Hsiao JS, Glatt-Deeley H. Modeling genomic imprinting disorders using induced pluripotent stem cells. Methods Mol Biol. 2016;1353:45\u201364.","journal-title":"Methods Mol Biol"},{"key":"23_CR179","doi-asserted-by":"crossref","first-page":"25368","DOI":"10.1038\/srep25368","volume":"6","author":"PF Chen","year":"2016","unstructured":"Chen PF, Hsiao JS, Sirois CL, Chamberlain SJ. RBFOX1 and RBFOX2 are dispensable in iPSCs and iPSC-derived neurons and do not contribute to neural-specific paternal UBE3A silencing. Sci Rep. 2016;6:25368.","journal-title":"Sci Rep"},{"key":"23_CR180","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nature13975","volume":"518","author":"L Meng","year":"2015","unstructured":"Meng L, Ward AJ, Chun S, Bennett CF, Beaudet AL, Rigo F. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. Nature. 2015;518:409\u201312.","journal-title":"Nature"},{"key":"23_CR181","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature10726","volume":"481","author":"HS Huang","year":"2011","unstructured":"Huang HS, Allen JA, Mabb AM, King IF, Miriyala J, Taylor-Blake B, et al. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature. 2011;481:185\u20139.","journal-title":"Nature"},{"key":"23_CR182","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.tins.2015.12.008","volume":"39","author":"DM Katz","year":"2016","unstructured":"Katz DM, Bird A, Coenraads M, Gray SJ, Menon DU, Philpot BD, et al. Rett syndrome: crossing the threshold to clinical translation. Trends Neurosci. 2016;39:100\u201313.","journal-title":"Trends Neurosci"},{"key":"23_CR183","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.neuron.2007.10.001","volume":"56","author":"M Chahrour","year":"2007","unstructured":"Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron. 2007;56:422\u201337.","journal-title":"Neuron"},{"key":"23_CR184","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/13810","volume":"23","author":"RE Amir","year":"1999","unstructured":"Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23:185\u20138.","journal-title":"Nat Genet"},{"key":"23_CR185","doi-asserted-by":"crossref","first-page":"C723","DOI":"10.1152\/ajpcell.00462.2010","volume":"300","author":"KW Dunn","year":"2011","unstructured":"Dunn KW, Kamocka MM, McDonald JH. A practical guide to evaluating colocalization in biological microscopy. AJP Cell Physiol. 2011;300:C723\u201342.","journal-title":"AJP Cell Physiol"},{"key":"23_CR186","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/cne.21264","volume":"501","author":"JM Dragich","year":"2007","unstructured":"Dragich JM, Kim YH, Arnold AP, Schanen NC. Differential distribution of the MeCP2 splice variants in the postnatal mouse brain. J Comp Neurol. 2007;501:526\u201342.","journal-title":"J Comp Neurol"},{"key":"23_CR187","first-page":"420","volume":"15","author":"F Della Ragione","year":"2016","unstructured":"Della Ragione F, Vacca M, Fioriniello S, Pepe G, D'Esposito M. MECP2, a multi-talented modulator of chromatin architecture. Brief Funct Genomics. 2016;15:420\u201331.","journal-title":"Brief Funct Genomics"},{"key":"23_CR188","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/gim.2015.100","volume":"18","author":"MA S\u00e1ez","year":"2016","unstructured":"S\u00e1ez MA, Fern\u00e1ndez-Rodr\u00edguez J, Moutinho C, Sanchez-Mut JV, Gomez A, Vidal E, et al. Mutations in JMJD1C are involved in Rett syndrome and intellectual disability. Genet Med. 2016;18:378\u201385.","journal-title":"Genet Med"},{"key":"23_CR189","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00439-016-1721-3","volume":"135","author":"M Lucariello","year":"2016","unstructured":"Lucariello M, Vidal E, Vidal S, Saez M, Roa L, Huertas D, et al. Whole exome sequencing of Rett syndrome-like patients reveals the mutational diversity of the clinical phenotype. Hum Genet. 2016;135:1343\u201354.","journal-title":"Hum Genet"},{"key":"23_CR190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.nbd.2014.03.009","volume":"67","author":"P Petazzi","year":"2014","unstructured":"Petazzi P, Akizu N, Garc\u00eda A, Estar\u00e1s C. Mart\u00ednez de Paz a, Rodr\u00edguez-Paredes M, et al. an increase in MECP2 dosage impairs neural tube formation. Neurobiol Dis. 2014;67:49\u201356.","journal-title":"Neurobiol Dis"},{"doi-asserted-by":"crossref","unstructured":"Meins M, Lehmann J, Gerresheim F, Herchenbach J, Hagedorn M, Hameister K, et al. Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett syndrome. J Med Genet. 2005;42:e12\u20132.","key":"23_CR191","DOI":"10.1136\/jmg.2004.023804"},{"key":"23_CR192","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.biopsych.2005.07.025","volume":"59","author":"T Gemelli","year":"2006","unstructured":"Gemelli T, Berton O, Nelson ED, Perrotti LI, Jaenisch R, Monteggia LM. Postnatal loss of methyl-CpG binding protein 2 in the forebrain is sufficient to mediate behavioral aspects of Rett syndrome in mice. Biol Psychiatry. 2006;59:468\u201376.","journal-title":"Biol Psychiatry"},{"key":"23_CR193","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.molmed.2014.03.004","volume":"20","author":"J Ausi\u00f3","year":"2014","unstructured":"Ausi\u00f3 J. Martinez de Paz a, Esteller M. MeCP2: the long trip from a chromatin protein to neurological disorders. Trends Mol Med. 2014;20:487\u201398.","journal-title":"Trends Mol Med"},{"key":"23_CR194","doi-asserted-by":"crossref","first-page":"6357","DOI":"10.1021\/acs.biochem.5b00790","volume":"54","author":"TG Kucukkal","year":"2015","unstructured":"Kucukkal TG, Yang Y, Uvarov O, Cao W, Alexov E. Impact of Rett syndrome mutations on MeCP2 MBD stability. Biochemistry. 2015;54:6357\u201368.","journal-title":"Biochemistry"},{"key":"23_CR195","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/hmg\/ddv496","volume":"25","author":"K Brown","year":"2016","unstructured":"Brown K, Selfridge J, Lagger S, Connelly J, De Sousa D, Kerr A, et al. The molecular basis of variable phenotypic severity among common missense mutations causing Rett syndrome. Hum Mol Genet. 2016;25:558\u201370.","journal-title":"Hum Mol Genet"},{"key":"23_CR196","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1093\/nar\/gkt213","volume":"41","author":"DP Stuss","year":"2013","unstructured":"Stuss DP, Cheema M, Ng MK, Martinez de Paz A, Williamson B, Missiaen K, et al. Impaired in vivo binding of MeCP2 to chromatin in the absence of its DNA methyl-binding domain. Nucleic Acids Res. 2013;41:4888\u2013900.","journal-title":"Nucleic Acids Res"},{"key":"23_CR197","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/humu.10194","volume":"21","author":"J Christodoulou","year":"2003","unstructured":"Christodoulou J, Grimm A, Maher T, Bennetts B. RettBASE: the IRSA MECP2 variation database-a new mutation database in evolution. Hum Mutat. 2003;21:466\u201372.","journal-title":"Hum Mutat"},{"key":"23_CR198","first-page":"266","volume":"9","author":"WA Gold","year":"2015","unstructured":"Gold WA, Christodoulou J. The utility of next-generation sequencing in Gene discovery for mutation-negative patients with Rett syndrome. Front Cell Neurosci. 2015;9:266.","journal-title":"Front Cell Neurosci"},{"key":"23_CR199","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/08830738030180100801","volume":"18","author":"S Naidu","year":"2003","unstructured":"Naidu S, Bibat G, Kratz L, Kelley RI, Pevsner J, Hoffman E, et al. Clinical variability in Rett syndrome. J Child Neurol. 2003;18:662\u20138.","journal-title":"J Child Neurol"},{"key":"23_CR200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/0883073807307077","volume":"23","author":"X Bao","year":"2008","unstructured":"Bao X, Jiang S, Song F, Pan H, Meirong Li WX-R. X chromosome inactivation in Rett syndrome and its correlations with MeCP2 mutations and phenotype. J Child Neurol. 2008;23:22\u20135.","journal-title":"J Child Neurol"},{"key":"23_CR201","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1523\/JNEUROSCI.2330-15.2016","volume":"36","author":"TW Huang","year":"2016","unstructured":"Huang TW, Kochukov MY, Ward CS, Merritt J, Thomas K, Nguyen T, et al. Progressive changes in a distributed neural circuit underlie breathing abnormalities in mice lacking MeCP2. J Neurosci. 2016;36:5572\u201386.","journal-title":"J Neurosci"},{"key":"23_CR202","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0896-6273(02)00768-7","volume":"35","author":"M Shahbazian","year":"2002","unstructured":"Shahbazian M, Young J, Yuva-Paylor L, Spencer C, Antalffy B, Noebels J, et al. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron. 2002;35:243\u201354.","journal-title":"Neuron"},{"key":"23_CR203","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.neuroscience.2007.02.009","volume":"146","author":"NA Stearns","year":"2007","unstructured":"Stearns NA, Schaevitz LR, Bowling H, Nag N, Berger UV, Berger-Sweeney J. Behavioral and anatomical abnormalities in Mecp2 mutant mice: a model for Rett syndrome. Neuroscience. 2007;146:907\u201321.","journal-title":"Neuroscience"},{"key":"23_CR204","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awl022","volume":"129","author":"GJ Pelka","year":"2006","unstructured":"Pelka GJ, Watson CM, Radziewic T, Hayward M, Lahooti H, Christodoulou J, et al. Mecp2 deficiency is associated with learning and cognitive deficits and altered gene activity in the hippocampal region of mice. Brain. 2006;129:887\u201398.","journal-title":"Brain"},{"key":"23_CR205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1258\/ebm.2010.010261","volume":"236","author":"G Calfa","year":"2011","unstructured":"Calfa G, Percy AK, Pozzo-Miller L. Experimental models of Rett syndrome based on Mecp2 dysfunction. Exp Biol Med. 2011;236:3\u201319.","journal-title":"Exp Biol Med"},{"key":"23_CR206","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fncel.2015.00145","volume":"9","author":"L Rietveld","year":"2015","unstructured":"Rietveld L, Stuss DP, McPhee D, Delaney KR. Genotype-specific effects of Mecp2 loss-of-function on morphology of layer V pyramidal neurons in heterozygous female Rett syndrome model mice. Front Cell Neurosci. 2015;9:145.","journal-title":"Front Cell Neurosci"},{"key":"23_CR207","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1152\/jn.00826.2007","volume":"99","author":"L Medrihan","year":"2008","unstructured":"Medrihan L, Tantalaki E, Aramuni G, Sargsyan V, Dudanova I, Missler M, et al. Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. J Neurophysiol. 2008;99:112\u201321.","journal-title":"J Neurophysiol"},{"key":"23_CR208","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neuron.2007.08.018","volume":"56","author":"HT Chao","year":"2007","unstructured":"Chao HT, Zoghbi HY, Rosenmund C. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron. 2007;56:58\u201365.","journal-title":"Neuron"},{"key":"23_CR209","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1523\/JNEUROSCI.4373-05.2005","volume":"25","author":"JC Viemari","year":"2005","unstructured":"Viemari JC, Roux JC, Tryba AK, Saywell V, Burnet H, Pe\u00f1a F, et al. Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. J Neurosci. 2005;25:11521\u201330.","journal-title":"J Neurosci"},{"key":"23_CR210","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1038\/npp.2014.136","volume":"39","author":"K Szczesna","year":"2014","unstructured":"Szczesna K, de la Caridad O, Petazzi P, Soler M, Roa L, Saez MA, et al. Improvement of the Rett syndrome phenotype in a MeCP2 mouse model upon treatment with levodopa and a dopa-decarboxylase inhibitor. Neuropsychopharmacology. 2014;39:2846\u201356.","journal-title":"Neuropsychopharmacology"},{"key":"23_CR211","doi-asserted-by":"crossref","first-page":"10359","DOI":"10.1523\/JNEUROSCI.0057-11.2011","volume":"31","author":"CS Ward","year":"2011","unstructured":"Ward CS, Arvide EM, Huang TW, Yoo J, Noebels JL, Neul JL. MeCP2 is critical within HoxB1 derived tissues of mice for normal lifespan. J Neurosci. 2011;31:10359\u201370.","journal-title":"J Neurosci"},{"key":"23_CR212","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1229223","volume":"339","author":"S Kim","year":"2013","unstructured":"Kim S, Brostr\u00f6mer E, Xing D, Jin J, Chong S, Ge H, et al. Probing allostery through DNA. Science. 2013;339:816\u20139.","journal-title":"Science"},{"key":"23_CR213","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrg3897","volume":"16","author":"MJ Lyst","year":"2015","unstructured":"Lyst MJ, Bird A. Rett syndrome: a complex disorder with simple roots. Nat Rev Genet. 2015;16:261\u201375.","journal-title":"Nat Rev Genet"},{"doi-asserted-by":"crossref","unstructured":"Beltr\u00e3o-Braga PCB, Muotri AR. Modeling autism spectrum disorders with human neurons. Brain Res. 2016;1\u20138","key":"23_CR214","DOI":"10.1016\/j.brainres.2016.01.057"},{"key":"23_CR215","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1002\/jcb.24597","volume":"114","author":"R Dajani","year":"2013","unstructured":"Dajani R, Koo SE, Sullivan GJ, Park IH. Investigation of Rett syndrome using pluripotent stem cells. J Cell Biochem. 2013;114:2446\u201353.","journal-title":"J Cell Biochem"},{"key":"23_CR216","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cell.2010.10.016","volume":"143","author":"MCN Marchetto","year":"2010","unstructured":"Marchetto MCN, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, et al. A model for neural development and treatment of rett syndrome using human induced pluripotent stem cells. Cell. 2010;143:527\u201339.","journal-title":"Cell"},{"key":"23_CR217","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12017-016-8421-y","volume":"18","author":"EWM Chin","year":"2016","unstructured":"Chin EWM, Marcy G, Yoon SI, Ma D, Rosales FJ, Augustine GJ, et al. Choline ameliorates disease phenotypes in human iPSC models of Rett syndrome. NeuroMolecular Med. 2016;18:364\u201377.","journal-title":"NeuroMolecular Med"},{"key":"23_CR218","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nbd.2015.01.001","volume":"76","author":"U Djuric","year":"2015","unstructured":"Djuric U, Cheung AYL, Zhang W, Mok RS, Lai W, Piekna A, et al. MECP2e1 isoform mutation affects the form and function of neurons derived from Rett syndrome patient iPS cells. Neurobiol Dis. 2015;76:37\u201345.","journal-title":"Neurobiol Dis"},{"key":"23_CR219","doi-asserted-by":"crossref","first-page":"14169","DOI":"10.1073\/pnas.1018979108","volume":"108","author":"KY Kim","year":"2011","unstructured":"Kim KY, Hysolli E, Park IH. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc Natl Acad Sci U S A. 2011;108:14169\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"23_CR220","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13041-015-0121-2","volume":"8","author":"T Andoh-Noda","year":"2015","unstructured":"Andoh-Noda T, Akamatsu W, Miyake K, Matsumoto T, Yamaguchi R, Sanosaka T, et al. Differentiation of multipotent neural stem cells derived from Rett syndrome patients is biased toward the astrocytic lineage. Mol Brain. 2015;8:31.","journal-title":"Mol Brain"},{"key":"23_CR221","first-page":"24","volume":"3","author":"AYL Cheung","year":"2012","unstructured":"Cheung AYL, Horvath LM, Carrel L, Ellis J. X-chromosome inactivation in Rett syndrome human induced pluripotent stem cells. Front Psychiatry. 2012;3:24.","journal-title":"Front Psychiatry"},{"key":"23_CR222","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1093\/hmg\/ddu008","volume":"23","author":"EC Williams","year":"2014","unstructured":"Williams EC, Zhong X, Mohamed A, Li R, Liu Y, Dong Q, et al. Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons. Hum Mol Genet. 2014;23:2968\u201380.","journal-title":"Hum Mol Genet"},{"key":"23_CR223","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/hmg\/ddv464","volume":"25","author":"C Del\u00e9pine","year":"2016","unstructured":"Del\u00e9pine C, Meziane H, Nectoux J, Opitz M, Smith AB, Ballatore C, et al. Altered microtubule dynamics and vesicular transport in mouse and human MeCP2-deficient astrocytes. Hum Mol Genet. 2016;25:146\u201357.","journal-title":"Hum Mol Genet"},{"key":"23_CR224","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1073\/pnas.1521255113","volume":"113","author":"ZN Zhang","year":"2016","unstructured":"Zhang ZN, Freitas BC, Qian H, Lux J, Acab A, Trujillo CA, et al. Layered hydrogels accelerate iPSC-derived neuronal maturation and reveal migration defects caused by MeCP2 dysfunction. Proc Natl Acad Sci U S A. 2016;113:3185\u201390.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"23_CR225","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/ejhg.2011.131","volume":"19","author":"M Amenduni","year":"2011","unstructured":"Amenduni M, De Filippis R, Cheung AYL, Disciglio V, Epistolato MC, Ariani F, et al. iPS cells to model CDKL5-related disorders. Eur J Hum Genet. 2011;19:1246\u201355.","journal-title":"Eur J Hum Genet"},{"key":"23_CR226","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/ncb2566","volume":"14","author":"S Ricciardi","year":"2012","unstructured":"Ricciardi S, Ungaro F, Hambrock M, Rademacher N, Stefanelli G, Brambilla D, et al. CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons. Nat Cell Biol. 2012;14:911\u201323.","journal-title":"Nat Cell Biol"},{"key":"23_CR227","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg1878","volume":"7","author":"T Bienvenu","year":"2006","unstructured":"Bienvenu T, Chelly J. Molecular genetics of Rett syndrome: when DNA methylation goes unrecognized. Nat Rev Genet. 2006;7:415\u201326.","journal-title":"Nat Rev Genet"},{"key":"23_CR228","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1866-1955-5-15","volume":"5","author":"KA Aldinger","year":"2013","unstructured":"Aldinger KA, Plummer JT, Levitt P. Comparative DNA methylation among females with neurodevelopmental disorders and seizures identifies TAC1 as a MeCP2 target gene. J Neurodev Disord. 2013;5:15.","journal-title":"J Neurodev Disord"},{"key":"23_CR229","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.stem.2013.09.001","volume":"13","author":"Y Li","year":"2013","unstructured":"Li Y, Wang H, Muffat J, Cheng AW, Orlando DA, Lov\u00e9n J, et al. Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell. 2013;13:446\u201358.","journal-title":"Cell Stem Cell"},{"key":"23_CR230","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.biopsych.2008.08.015","volume":"65","author":"S Akbarian","year":"2009","unstructured":"Akbarian S, Huang HS. Epigenetic regulation in human brain-focus on histone lysine methylation. Biol Psychiatry. 2009;65:198\u2013203.","journal-title":"Biol Psychiatry"},{"key":"23_CR231","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025255","volume":"6","author":"G Ananiev","year":"2011","unstructured":"Ananiev G, Williams EC, Li H, Chang Q. Isogenic pairs of wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome patients as in vitro disease model. PLoS One. 2011;6:e25255.","journal-title":"PLoS One"},{"key":"23_CR232","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrd4738","volume":"14","author":"EA Kimbrel","year":"2015","unstructured":"Kimbrel EA, Lanza R. Current status of pluripotent stem cells: moving the first therapies to the clinic. Nat Rev Drug Discov. 2015;14:681\u201392.","journal-title":"Nat Rev Drug Discov"},{"key":"23_CR233","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.stem.2015.12.002","volume":"18","author":"WT Hendriks","year":"2016","unstructured":"Hendriks WT, Warren CR, Cowan CA. Genome editing in human pluripotent stem cells: approaches, pitfalls, and solutions. Cell Stem Cell. 2016;18:53\u201365.","journal-title":"Cell Stem Cell"},{"key":"23_CR234","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cell.2016.08.056","volume":"167","author":"XS Liu","year":"2016","unstructured":"Liu XS, Wu H, Ji X, Stelzer Y, Wu X, Czauderna S, et al. Editing DNA methylation in the mammalian genome. Cell. 2016;167:233\u201347.e17.","journal-title":"Cell"},{"key":"23_CR235","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.stem.2016.06.017","volume":"19","author":"N Tapia","year":"2016","unstructured":"Tapia N, Sch\u00f6ler HR. Molecular obstacles to clinical translation of iPSCs. Cell Stem Cell. 2016;19:298\u2013309.","journal-title":"Cell Stem Cell"},{"key":"23_CR236","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.stem.2016.02.011","volume":"18","author":"R Passier","year":"2016","unstructured":"Passier R, Orlova V, Mummery C. Complex tissue and disease modeling using hiPSCs. Cell Stem Cell. 2016;18:309\u201321.","journal-title":"Cell Stem Cell"}],"container-title":["Advances in Experimental Medicine and Biology","Neuroepigenomics in Aging and Disease"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-53889-1_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T18:01:37Z","timestamp":1659031297000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-53889-1_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319538884","9783319538891"],"references-count":236,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-53889-1_23","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2017]]}}}